These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
578 related articles for article (PubMed ID: 33248323)
1. Potential Unreliability of Uncommon ALK, ROS1, and RET Genomic Breakpoints in Predicting the Efficacy of Targeted Therapy in NSCLC. Li W; Guo L; Liu Y; Dong L; Yang L; Chen L; Liu K; Shao Y; Ying J J Thorac Oncol; 2021 Mar; 16(3):404-418. PubMed ID: 33248323 [TBL] [Abstract][Full Text] [Related]
2. CD74/SLC34A2-ROS1 Fusion Variants Involving the Transmembrane Region Predict Poor Response to Crizotinib in NSCLC Independent of TP53 Mutations. Li W; Fei K; Guo L; Wang Y; Shu C; Wang J; Ying J J Thorac Oncol; 2024 Apr; 19(4):613-625. PubMed ID: 38070598 [TBL] [Abstract][Full Text] [Related]
3. Intergenic Breakpoints Identified by DNA Sequencing Confound Targetable Kinase Fusion Detection in NSCLC. Li W; Liu Y; Li W; Chen L; Ying J J Thorac Oncol; 2020 Jul; 15(7):1223-1231. PubMed ID: 32151779 [TBL] [Abstract][Full Text] [Related]
4. Multicenter evaluation of an automated, multiplex, RNA-based molecular assay for detection of ALK, ROS1, RET fusions and MET exon 14 skipping in NSCLC. Melchior L; Hirschmann A; Hofman P; Bontoux C; Concha A; Mrabet-Dahbi S; Vannuffel P; Watkin E; Putzová M; Scarpino S; Cayre A; Martin P; Stoehr R; Hartmann A Virchows Arch; 2024 Apr; 484(4):677-686. PubMed ID: 38492039 [TBL] [Abstract][Full Text] [Related]
5. Detection of clinically actionable gene fusions by next-generation sequencing-based RNA sequencing of non-small cell lung cancer cytology specimens: A single-center experience with comparison to fluorescence in situ hybridization. Diks J; Tang Z; Altan M; Anderson S; Chen H; Rashid A; Yang RK; Routbort MJ; Patel KP; Toruner GA; Medeiros LJ; Tang G; Luthra R; Roy-Chowdhuri S Cancer Cytopathol; 2024 Jan; 132(1):41-49. PubMed ID: 37747438 [TBL] [Abstract][Full Text] [Related]
6. A single-tube multiplexed assay for detecting ALK, ROS1, and RET fusions in lung cancer. Lira ME; Choi YL; Lim SM; Deng S; Huang D; Ozeck M; Han J; Jeong JY; Shim HS; Cho BC; Kim J; Ahn MJ; Mao M J Mol Diagn; 2014 Mar; 16(2):229-43. PubMed ID: 24418728 [TBL] [Abstract][Full Text] [Related]
7. Reliability analysis of exonic-breakpoint fusions identified by DNA sequencing for predicting the efficacy of targeted therapy in non-small cell lung cancer. Li W; Wan R; Guo L; Chang G; Jiang D; Meng L; Ying J BMC Med; 2022 May; 20(1):160. PubMed ID: 35534835 [TBL] [Abstract][Full Text] [Related]
9. Expression of C-terminal ALK, RET, or ROS1 in lung cancer cells with or without fusion. Furugaki K; Mochizuki M; Kohno M; Shu S; Harada N; Yoshimura Y BMC Cancer; 2019 Apr; 19(1):301. PubMed ID: 30943926 [TBL] [Abstract][Full Text] [Related]
10. [Detection of ALK, ROS1 and RET fusion genes in non-small cell lung cancer patients and its clinicopathologic correlation]. Zhong S; Zhang H; Bai D; Gao D; Zheng J; Ding Y Zhonghua Bing Li Xue Za Zhi; 2015 Sep; 44(9):639-43. PubMed ID: 26705279 [TBL] [Abstract][Full Text] [Related]
11. Molecular and clinicopathological characteristics of ROS1-rearranged non-small-cell lung cancers identified by next-generation sequencing. Cui M; Han Y; Li P; Zhang J; Ou Q; Tong X; Zhao R; Dong N; Wu X; Li W; Jiang G Mol Oncol; 2020 Nov; 14(11):2787-2795. PubMed ID: 32871626 [TBL] [Abstract][Full Text] [Related]
12. RET Fluorescence In Situ Hybridization Analysis Is a Sensitive but Highly Unspecific Screening Method for RET Fusions in Lung Cancer. Radonic T; Geurts-Giele WRR; Samsom KG; Roemen GMJM; von der Thüsen JH; Thunnissen E; Meijssen IC; Sleddens HFBM; Dinjens WNM; Boelens MC; Weijers K; Speel EJM; Finn SP; O'Brien C; van Wezel T; Cohen D; Monkhorst K; Roepman P; Dubbink HJ J Thorac Oncol; 2021 May; 16(5):798-806. PubMed ID: 33588111 [TBL] [Abstract][Full Text] [Related]
13. ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: a comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features. Pan Y; Zhang Y; Li Y; Hu H; Wang L; Li H; Wang R; Ye T; Luo X; Zhang Y; Li B; Cai D; Shen L; Sun Y; Chen H Lung Cancer; 2014 May; 84(2):121-6. PubMed ID: 24629636 [TBL] [Abstract][Full Text] [Related]
14. Usefulness of an RNA extraction-free test for the multiplexed detection of Damiola F; Alberti L; Mansuet-Lupo A; Damotte D; Hofman V; Tixier L; Penault-Llorca F; Rouquette I; Vignaud JM; Cazes A; Forest F; Begueret H; Gibault L; Badoual C; Cayre A; Taranchon-Clermont E; Duc A; Mc Leer A; Lantuejoul S Expert Rev Mol Diagn; 2023; 23(12):1283-1291. PubMed ID: 37906110 [TBL] [Abstract][Full Text] [Related]
15. ALK, ROS1 and RET rearrangements in lung squamous cell carcinoma are very rare. Zhao W; Choi YL; Song JY; Zhu Y; Xu Q; Zhang F; Jiang L; Cheng J; Zheng G; Mao M Lung Cancer; 2016 Apr; 94():22-7. PubMed ID: 26973202 [TBL] [Abstract][Full Text] [Related]
16. Resistance Mechanisms to Targeted Therapies in McCoach CE; Le AT; Gowan K; Jones K; Schubert L; Doak A; Estrada-Bernal A; Davies KD; Merrick DT; Bunn PA; Purcell WT; Dziadziuszko R; Varella-Garcia M; Aisner DL; Camidge DR; Doebele RC Clin Cancer Res; 2018 Jul; 24(14):3334-3347. PubMed ID: 29636358 [No Abstract] [Full Text] [Related]
17. Ligation-dependent RT-PCR: a new specific and low-cost technique to detect ALK, ROS, and RET rearrangements in lung adenocarcinoma. Piton N; Ruminy P; Gravet C; Marchand V; Colasse É; Lamy A; Naoures Mear CL; Bibeau F; Marguet F; Guisier F; Salaün M; Thiberville L; Jardin F; Sabourin JC Lab Invest; 2018 Mar; 98(3):371-379. PubMed ID: 29251734 [TBL] [Abstract][Full Text] [Related]
18. Novel targets in non-small cell lung cancer: ROS1 and RET fusions. Gainor JF; Shaw AT Oncologist; 2013; 18(7):865-75. PubMed ID: 23814043 [TBL] [Abstract][Full Text] [Related]
19. Cell block-based RNA next generation sequencing for detection of gene fusions in lung adenocarcinoma: An institutional experience. Wei S; Talarchek JN; Huang M; Gong Y; Du F; Ehya H; Flieder DB; Patchefsky AS; Wasik MA; Pei J Cytopathology; 2023 Jan; 34(1):28-34. PubMed ID: 36062384 [TBL] [Abstract][Full Text] [Related]
20. Decoding Tumor Phenotypes for ALK, ROS1, and RET Fusions in Lung Adenocarcinoma Using a Radiomics Approach. Yoon HJ; Sohn I; Cho JH; Lee HY; Kim JH; Choi YL; Kim H; Lee G; Lee KS; Kim J Medicine (Baltimore); 2015 Oct; 94(41):e1753. PubMed ID: 26469915 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]